The goal of this project is to, for the first time, create a joint Nordic long-term academic collaboration on pandemic preparedness using advanced mathematical modelling and systematically collected health data from a broad range of sources.
Tidligere på måneden var der deadline på et opslag inden for COVID-19-forskning, og antallet af ansøgninger er nu opgjort. Opslaget er et samarbejde mellem forskningsfinansierer fra de nordiske lande, Estland og Letland.
På initiativ fra nordiske medicinske dekaner har Det nordiske samarbejdsorgan for medicinsk forskning (NOS-M) besluttet at finansiere et nordisk onlinekursus i persontilpasset medicin til medicinstuderende.
På grund af den igangværende COVID-19-pandemi er der et stort behov for ny viden relateret til SARS-CoV-2 virusset. Det skal fire nye samarbejdsprojekter nu have fokus på ved hjælp af sundhedsdata.
A call for proposals for funding of Nordic and Nordic-Estonian/Latvian collaboration projects on health data research on COVID-19 is now announced. The application deadline is 16 June 2020 13 CEST
NORDeHEALTH aims to give patients online access to their electronic health records (PAEHR) and increase self-management and transparencyin healthcare. The goal is to enable further digitalization of the public health sector by providing concrete feedback to the national. authorities in the respective countries, provide guidelines and frameworks for design, implementation and evaluation of personal eHealthservices (PeHS).
The aims of the ALLTogether study are to improve survival and quality of survival for children and young adults with ALL. ALL in young people has excellent outcome with >90% survival in children and about 75% in young adults. However, patients still die of diseases after relapse as a result of under-treatment.
Globally, the leading cause of years of life lost is ischemic heart disease (IHD). In the EU 13.2 mio. patients are diagnosed with IHD(1) of these 700,000 live in the Nordic countries. IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance. IHD is considered a chronic disease and may progress despite current optimal treatment.
